Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

ARR-217 · MRG007

Antibody-drug conjugate · Cytotoxic, directed at cadherin-17 (CDH17) · developed by ArriVent BioPharma

Phase 1 Most advanced trial

AVBP Developer

1 Registered trials

What is ARR-217?

ARR-217 (MRG007) is an antibody-drug conjugate made of a humanized IgG1 antibody that binds cadherin-17 (CDH17), site-specifically conjugated to the topoisomerase-1 inhibitor exatecan. After binding and internalization into CDH17-expressing tumor cells, exatecan is released and inhibits topoisomerase 1, blocking DNA replication. It is being studied in solid tumors, colorectal cancer, gastric cancer and pancreatic cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: MRG007
Drug type: Antibody-drug conjugate
Targets: cadherin-17 (CDH17), DNA topoisomerase 1 (TOP1) (secondary target)
Mechanism: Cytotoxic, directed at cadherin-17 (CDH17)
Pathways: DNA replication inhibition, cell cycle arrest, apoptosis
Therapy area: Oncology
Developer: ArriVent BioPharma, Inc. (AVBP)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT07066657	Phase 1	Locally Advanced or Metastatic Solid Tumors	Recruiting	AVBP

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Colorectal CancerGastric CancerLocally Advanced or Metastatic Solid TumorsPancreatic Cancer

More from ArriVent BioPharma

ARR-002 Phase 1 EGFR-TKI inhibitor based on investigator's choice Phase 3 Firmonertinib Phase 3

Sources

Updated Oct 11, 2026. Something wrong or missing? Report it on the AVBP page.

Follow AVBP, the company behind ARR-217

See AVBP's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

AVBP catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z